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Significance statement 
Previous experimental and observational data have raised concerns that intravenous iron could 
increase the risk of infections. In the PIVOTAL trial, 2141 hemodialysis patients were 
randomized to either a high-dose or a low-dose intravenous iron regimen, and there was no 
evidence of an increased incidence of infection when analyzed as ‘All infections’, 
‘Hospitalization for infections’, and ‘Death from infection’. Given the potential cardiovascular 
benefits seen in PIVOTAL, this analysis provides reassurance for administering higher doses of 
IV iron than are currently given in many units worldwide. 
 
Abstract    
Background   
There are concerns about an increased risk of infections with intravenous iron. The PIVOTAL 
trial randomized 2141 patients undergoing maintenance hemodialysis for end-stage kidney 
failure to a high-dose or a low-dose intravenous iron regimen, with a primary composite outcome 
of all-cause death, heart attack, stroke, or heart failure hospitalization. Comparison of infection 
rates between the two groups was a pre-specified secondary analysis. 
Methods 
Secondary endpoints included any infection, hospitalization for infection, and death from 
infection; cumulative event rates were calculated for all three endpoints. The interaction between 
IV iron dose and vascular access (fistula versus catheter) was also interrogated. 
Results 
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There was no difference in event rates (63.3 per 100 patient years high-dose versus 69.4 low-
dose) for “all infections” (46.5% versus 45.5%; HR 0.98; CI 0.87, 1.11; p=0.80) and 
hospitalization for infection (HR 0.99; CI 0.82, 1.16; p=0.92) between the two groups. Compared 
to patients with an arteriovenous fistula, patients dialyzing via a catheter had a higher incidence 
of having any infection, hospitalization for infection, or fatal infection, but there was no impact 
of IV iron dosing on these outcomes. 
Conclusions 
Infection rates were identical in the high-dose and low-dose IV iron groups. There was a strong 
association between the risk of a first cardiovascular event and a recent infection. There were no 
consistent relationships between iron dose, ferritin/TSAT and risk of infection.  
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INTRODUCTION 
 
Intravenous iron is widely used to treat iron deficiency, either when oral iron has failed to correct 
an iron deficit or is causing unacceptable side-effects. Furthermore, in patients receiving 
maintenance hemodialysis1 and in those with heart failure,2 it has become incorporated into 
standard-of-care. However, there are safety concerns with this treatment.3 Because this mode of 
administration bypasses the normal physiological hepcidin-regulated process of iron absorption 
from the gut,4 there is the potential for iatrogenic iron overload, which is associated with an 
increased infection risk. There have also been concerns about the potential for intravenous iron 
to exacerbate infections more acutely (notably gram negative organisms, mycobacteria, fungi, 
Yersinia sp), both by enhancing bacterial proliferation and by reducing natural defense 
mechanisms.5 Several studies have shown that within hours of intravenous administration, there 
is a reduction in bacterial killing by neutrophils.6  Observational studies examining the 
relationship between intravenous iron administration and infections have produced conflicting 
results.7-10 Whilst some support an increased risk,7, 8 others do not.9, 10 A meta-analysis of 78 
randomized controlled trials of intravenous iron compared to oral iron or no iron 
supplementation for treatment of anemia or prevention of blood transfusion suggested that 
intravenous iron was associated with a significantly higher incidence of infection compared with 
either oral iron or no iron supplementation amongst 4400 patients in 24 studies (RR; 95% CI): 
1.33; 1.10-1.64).11 A subsequent meta-analysis in dialysis patients found no association between 
an increased incidence of infection with intravenous iron, although this included only four 
studies, all of which were small and of short duration.12 
The Proactive IV irOn Therapy in hemodiALysis patients (PIVOTAL) study, the largest 
randomized controlled trial of iron therapy in any patient population,13 provided an ideal 
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opportunity to examine infection risk with two different treatment strategies with intravenous 
iron. In this trial, the safety and efficacy of a proactive, high-dose intravenous iron regimen, 
compared with a reactive, low-dose intravenous iron regimen, were examined in 2141 
hemodialysis patients, followed up for a median of 2.1 years (maximum 4.4 years). Although the 
primary endpoint was a composite of all-cause death and non-fatal cardiovascular events, key 
safety secondary endpoints focused on infection risk. The statistical analysis plan pre-specified 
analysis of the infection secondary endpoints.13 
 
METHODS  
A full description of the study methods, including the study protocol and statistical analysis plan 
has previously been reported, 13, 14 and is available at NEJM.org.13 In brief, 2141 patients were 
randomized to a high-dose (400 mg monthly, with a cut-off ferritin of 700 µg/L and/or TSAT of 
40%) or a low-dose (0 to 400 mg monthly) iron regimen. Importantly, the protocol instructed 
investigators to withhold iron if the patient developed a new infection deemed sufficient to 
contraindicate the use of intravenous iron. In such cases, iron therapy was resumed when the 
investigator judged it safe. Patients with active infection at the time of recruitment were also 
excluded from the trial. Follow-up was for a median of 2.1 years (maximum 4.4 years).  The 
median cumulative iron dose at one year was 3.8 g in the high-dose arm and 1.8 g in the low-
dose arm. The median monthly iron doses in the respective groups were 264 mg versus 145 
mg.13 
Safety secondary endpoints included (i) any infection, (ii) hospitalization for infection, and (iii) 
death from infection. Any infection was determined from investigator judgement, and included 
patients with mild respiratory, urinary, or catheter infections not considered severe enough to 
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require hospitalization, but also including all infections causing hospitalization or death. 
Hospitalization for infection was defined as an admission to hospital caused by an episode of 
infection, and lasting ≥ 24 hours. Death from infection was determined from the investigator 
serious adverse event reports, and was adjudicated by the study endpoint adjudication committee. 
 
Statistical Methods 
Baseline characteristics are summarized as mean (standard deviation) or median (lower quartile, 
upper quartile) for continuous variables, and counts and percentages for categorical data. The 
data are given for the total group and split on the basis of vascular access status at baseline 
(catheter versus fistula or graft), with p-values for between-group difference based on two 
sample t-tests or chi-squared tests as appropriate (Table 1). 
Time to first event for any infection, hospitalized infection and fatal infection were analyzed 
using Cox proportional hazard models adjusting for randomization stratification variables 
(vascular access [dialysis catheter vs. arteriovenous fistula or graft], diagnosis of diabetes [yes 
vs. no], and duration of hemodialysis treatment [<5 months vs. ≥5 months]) and hazard ratios 
and 95% confidence intervals calculated for treatment effects. Time to event curves were 
calculated as cumulative incidence functions adjusting for the competing risk of deaths not 
included in the outcome being analyzed. Rates (per 100 patient years) of recurrent infection of 
any kind and hospitalized infections were compared between treatment groups using the method 
of Lin, Wei, Ying and Yang.15 
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Because infection rates (usually Staphylococcus sp.) are more common in patients using dialysis 
catheters compared with those relying on native arteriovenous fistulae,16 the association between 
type of vascular access and infection rates was also examined. Type of vascular access was 
recorded monthly on the electronic case record form during the trial. To simplify the analysis, 
vascular access was analyzed as ‘catheter at baseline and for every month of the study follow-up’ 
versus ‘arteriovenous fistula at baseline and for every month of the study follow-up’, thus 
excluding any patients who had periods using a catheter and periods using a fistula. Cox models 
were used to compare the time to first events for all infections and hospitalized infections 
between these two groups. The models included terms for the access groups, randomized 
treatment group, the stratification variables for diabetes and duration of hemodialysis treatment 
and an interaction term between access group and the randomized treatment group.  Cumulative 
incidence functions split by access group and by access group and randomized treatment group 
were determined for each endpoint adjusting for the competing risk of deaths not included in the 
outcome being studied. 
 
We created time-varying covariates specifying at a given point in time the most recent iron dose 
and the current total iron dose. We then determined the association between each of these 
variables and the outcome of a first infection in time-varying Cox regression models separately 
in each treatment group adjusting for baseline stratification variables defined by diabetes status, 
time on dialysis, and vascular access status. These analyses were repeated for the outcome of 
hospitalized infection. These analyses were also repeated substituting most recent ferritin and 
TSAT levels for iron dose.   
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The association between a recent infection and risk of a first cardiovascular event was 
investigated using infection in the previous 30 days as a time-varying covariate in a Cox 
regression model adjusted for treatment group and baseline stratification variables. (Figure 1). 
Cardiovascular events were adjudicated by the trial endpoint adjudication committee blinded to 
the treatment assignment. The analysis was repeated for infections requiring hospitalization, and 
for any infection. Results reported included hazard ratios, 95% confidence intervals and p-values 
for the association between presence of a recent infection and a cardiovascular event. 
 
In the vast majority of infections reported, particularly those not requiring hospitalization (but 
also, for example, in patients hospitalized for pneumonia), no causal infectious agent was 
identified via culture of fluid, tissue or blood. Infections were classified according to main organ 
primarily involved. Where an infectious agent was identified, these were subdivided into Gram-
positive bacteria, Gram-negative bacteria, viruses, and fungi or parasites. Further data on specific 
organisms is also reported when available. 
 
 
 
RESULTS 
 
Rates of infectious events  
For ‘All infection episodes”, there were 508 first events (46.5%) in the proactive high-dose arm 
versus 477 first events (45.5%) in the reactive low-dose arm (HR 0.98; CI 0.87, 1.11; p=0.80) 
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(Figure 2). This represented an incidence of 63.3 per 100 patient years for the high-dose arm 
versus 69.4 per 100 patient years for the low-dose arm. Corresponding results for 
‘Hospitalizations for infections’ were 323 first events (29.6%) in the proactive high-dose arm 
versus 307 first events (29.3%) in the reactive low-dose arm (HR 0.99; CI 0.82, 1.16; p=0.92).  
For ‘Death from infections’, there were 46 events (4.21%) in the proactive high-dose arm versus 
41 first events (3.91%) in the reactive low-dose arm (HR 1.04; CI 0.69, 1.59; p=0.84).   
Cumulative event curves for ‘all infection episodes’ were not distinguishable between the high-
dose versus low-dose treatment assignment arms (Figure 3). 20% of the patients had a first event 
within the first 6 months, 40% had a first event by 1.5 years, and by 3.5 years, 60% of patients 
had an infection episode. For ‘hospitalized infections’, 20% of the patients had a first event 
within the first year, and 40% had a first event by 3.5 years, with no evidence of a difference 
between the two groups. For ‘fatal infections’, the event rate was low with no evidence of a 
difference between the groups, with most deaths occurring after one year of follow-up. 
Infection rates for dialysis catheter versus arteriovenous fistula patients 
Of the 2141 patients in the study, 260 had a dialysis catheter throughout the entire study period, 
compared with 946 patients who had an arteriovenous fistula throughout the duration of the 
study. Cumulative event curves for each of the three infection endpoints are shown in Figure 4. 
As might be expected, compared to patients with an arteriovenous fistula, patients with a catheter 
had a higher incidence of having any infection (HR: 1.57; 95% CI: 1.27 - 1.94; p < 0.001), a 
higher incidence of hospitalization for an infection (HR: 1.60; 95% CI: 1.22 - 2.09; P < 0 .001), 
and a higher risk of having a fatal infection (HR 2.33; 95% CI: 1.28 - 4.25; p < 0.001). 
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When the risk of infections with ‘catheter only’ versus ‘fistula only’ was compared in relation to 
the treatment assignment arm, no differences were seen. Thus, patients who were dialyzed on a 
catheter throughout the entire period of the study had a similar risk of contracting an infection 
with high-dose iron versus low-dose iron; the same is true for patients dialyzing on an 
arteriovenous fistula for the entire study (Figures 5 and 6), and this held true for all three 
infection endpoints. 
 
Association between indices reflecting iron status and infectious event/outcome 
There was no evidence of an association between iron status and infection outcomes. The hazard 
ratios, 95% CIs, and p-values are given per 100 unit higher ferritin level and per 5 unit higher 
TSAT level (Table 2). 
 
Association between a recent infection and risk of a first cardiovascular event  
In the time-updated covariate-adjusted analysis, there were strong associations between the risk 
of a first cardiovascular event and any infection in the previous 30 days (HR 2.83, 95% CI 2.04, 
3.92, p < 0.0001); the same was true for hospitalization for infection (HR = 2.74, 95% CI 1.54, 
4.88, p = 0.0006). 
 
Characterization of infectious agent 
In total, there were 1837 documented infection episodes for any infection. Grouped by organ 
involvement, 40.2% were of the respiratory tract; 19.4% unclassified; 20.3% skin and soft tissue 
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and 12.3% urinary tract related. A total of 144 episodes had an organism identified (64 Gram-
positive; 58 Gram-negative; and 22 viral). For those infections leading to hospitalization, there 
was a total of 1130 episodes: 39.4% respiratory; 15.7% sepsis (no specific organ characterized); 
8.6 % soft tissue or skin and 11.7% unclassified. In this case there were a total of 97 events (23 
Gram-positive; 32 Gram-negative; 39 viral; and 3 fungal/parasitic).  Hence, where the infectious 
agent was identified, similar proportions of Gram-positive organisms, Gram-negative organisms, 
and viral agents were seen (Figure 7). 
 
 
DISCUSSION 
 
 
The PIVOTAL trial showed no impact of the higher dosing intravenous iron protocol on 
infection incidence in a large hemodialysis population. Despite the high-dose iron arm receiving 
more than double the dose of intravenous iron over the first year and nearly double the median 
monthly intravenous iron dose overall, no increase in infection incidence was observed, 
compared with the low-dose iron group. Three infection endpoints were assessed (‘All 
infections’, ‘Hospitalizations for infections’, and’ Fatal infections’), and the consistency of the 
findings across all of these provides reassurance that there is no impact of administering higher 
doses of intravenous iron on incidence of infections. 
These findings are at variance with multiple reports in the experimental literature suggesting that 
iron might enhance bacterial and fungal proliferation,5 and also reduce bacterial defense 
mechanisms. 6 Using the same IV iron preparation that was used in PIVOTAL (iron sucrose), 
Deicher et al6 found that within the first two hours of dialysis, the percentage of E. coli killed by 
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neutrophils significantly decreased in the group randomized to IV iron versus no iron. 
Observational studies examining the relationship between IV iron administration and infections 
have produced conflicting results, with some for, and others against, an association.7-10 Several 
previous reports have indicated that patients dialyzing via a catheter have a greatly enhanced 
infection risk compared to those using an arteriovenous fistula.16 Similar findings were obtained 
in PIVOTAL, with significant increases in all three infection endpoints. However, the trial also 
allowed us to examine whether there was any impact of iron dosing on the infection risk in 
relation to vascular access. In both subpopulations of patients (catheter only and fistula only), 
there was no impact of iron dosing on the incidence of infection across all three endpoints; this 
may be reassuring for certain subsets of vulnerable patients such as the frail elderly dialyzing via 
long-term catheters. 
The design of the study also allowed us to examine whether there was any association between 
an infection episode and a subsequent cardiovascular event, which has been reported in a number 
of observational studies both outside the dialysis setting,17-19 and in a large US-based dialysis 
cohort.20 
An analysis of the ARIC (Atherosclerosis Risk in Community) study,17 for example, showed that 
both inpatient and outpatient infections appeared to be a trigger for a cardiovascular event. In 
1312 incident coronary heart disease and 727 incident stroke cases, the 30 days odds ratio for the 
event following an inpatient infection was 8.39 (4.92-14.41) and outpatient infection 2.69 (2.14-
3.37) compared to a control period.  
In a non-dialysis CKD prospective cohort study (Canadian Study of Prediction of Risk and 
Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time; CanPREDDICT), 
Cheikh Hassan et al18 found that infection (i.e. positive culture, use of antibiotics, or 
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hospitalization for infection) was associated with an increased risk of cardiovascular events, end-
stage kidney disease and mortality (median follow-up 3.5 years). 
In a cohort of 16,874 hemodialysis patients in the US Renal Data System aged 65 to 100 years, 
Dalrymple and colleagues estimated the relative incidence of a cardiovascular event within 90 
days after an infection-related hospitalization as compared with other times not within 90 days of 
such a hospitalization. The authors found that the risk of a cardiovascular event was increased by 
25% in the first 30 days after an infection and was overall increased 18% in the 90 days after an 
infection-related hospitalization relative to control periods.20 
In the PIVOTAL trial, we confirmed this association in a hemodialysis population randomized to 
two different IV iron regimens. The strengths of our analysis include the facts that data were 
collected prospectively via an electronic case record form and that cardiovascular endpoints were 
adjudicated by a blinded endpoint committee. As with all previous studies examining this 
association, this does not prove causality. An alternative explanation is that patients at risk of a 
future cardiovascular event are more susceptible to infections, although this has less biological 
plausibility. 
The lack of any impact of the exploratory analysis of iron dose on infection risk is perhaps no 
surprise. Since there was no effect overall in the randomized study, it would perhaps have been 
surprising to have found any significant association in these analyses. The same is true with the 
analysis of iron markers on infection risk. Because the randomized treatment induced significant 
differences in ferritin and TSAT between the groups and there was no difference in infections, 
there is no evidence of a causal relationship between ferritin concentrations or TSAT and 
infection. Hence, any associations in the analyses can be attributed to reverse causality (during 
inflammatory states, the serum ferritin increases as an acute phase protein, and the transferrin 
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saturation is reduced). Infection leads to raised ferritin and reduced TSAT, and hence one might 
have expected a recent raised ferritin or lower TSAT observed during an evolving infection to be 
associated with an increased risk of subsequent infection. Given a possibly longer delay in 
hospital admission after the initial onset of infection, the association might be stronger in 
hospitalized infection.  
The strengths of this study include the study design (randomized controlled), the prospective data 
capture via an electronic database on a monthly basis, and the adjudication of cardiovascular 
events by an independent committee blinded to the treatment assignment.  There are, however, a 
few limitations to the study. The first is that this is a secondary analysis and not the primary aim 
of the study, albeit the analysis was pre-specified. Although this is the largest randomized trial of 
iron in any patient population, it was conducted in a cohort of patients receiving hemodialysis. 
This is a very specific group of patients, with different infection risks and profiles from other 
patient groups. Given the incidence of infection in this group of patients, it was a good way to 
test the hypothesis of iron treatment on the risk of infection, but extrapolating the findings to 
other patient populations may not be justified. The intravenous iron preparation used in 
PIVOTAL was iron sucrose. Whether the findings in this study can be extrapolated to other IV 
iron preparations is unknown. In particular, whether the doses of iron sucrose used in PIVOTAL 
are equivalent to the same doses of other iron preparations is highly questionable, and caution 
should be exercised in this regard. The follow-up, although adequate, also does not allow 
extrapolation of results beyond the study period (median follow up 2.1 years; maximum follow-
up 4.4 years). We acknowledge that only 56% of the population could be included in the analysis 
comparing patients with ‘Fistula only’ versus ‘Catheter only, and therefore there may potentially 
be issues with a lack of power to be certain of this finding. Finally, the study does not exclude 
16 
 
the possibility that even higher doses of IV iron could be harmful in exacerbating infections, as 
has recently been found in an observational study.8 
Nevertheless, the clarity of the findings across all three infection endpoints, as well as the 
closeness of the hazard ratios to 1.0 provides reassurance that patients recently starting 
hemodialysis exposed to an IV iron regimen of 400 mg of iron sucrose monthly, maintaining 
ferritin concentrations around 600-700 µg/L, were not at increased risk of infections compared to 
the less intensive iron strategy. Given the potential cardiovascular benefits seen in PIVOTAL,13 
this analysis provides further support for administering higher doses of IV iron than are currently 
given in many units worldwide. 
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Gloucestershire Royal Hospital, Gloucestershire: Jim Moriarty; Guy’s & St Thomas’ Hospital, 
London: Paramit Chowdury; Hammersmith Hospital, London: Megan Griffiths; Heartlands 
Hospital, Birmingham: Indranil Dasgupta; Hull Royal Infirmary, Hull: Sunil Bhandari; Kent & 
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Legends to Figures 
 
Figure 1. Schematic representation of the methodology used in the analysis of the association 
between a recent infection and risk of a first cardiovascular event. Infection in the previous 30 
days was used as a time-varying covariate, in a Cox regression model adjusted for treatment 
group and baseline stratification variables (diabetes status, time on dialysis and vascular access 
status). Scenarios for 4 different patients shown. (CV = cardiovascular; Pt = Patient). 
 
Figure 2. Comparison of number and percentage of events (*expressed as hazard ratio), and 
number of recurrent events per 100 patient-years (†expressed as a rate ratio), for ‘All infections’ 
and ‘Hospitalization for infection’, and number and percentage of fatal infections (*expressed as 
hazard ratio), between the high-dose intravenous iron group and the low-dose iron group. 
 
Figure 3. Comparison of cumulative event curves between the high-dose intravenous iron group 
and the low-dose iron group for ‘All infections’, ‘Hospitalization for infection’, and ‘Death from 
infection’. 
 
Figure 4. Comparison of cumulative event curves between patients dialyzing on a fistula only 
for the whole study versus those dialyzing on a catheter only for ‘All infections’, 
‘Hospitalization for infection’, and ‘Death from infection’. 
 
Figure 5. Comparison of cumulative event curves between patients dialyzing on a fistula only 
for the whole study versus those dialyzing on a catheter only for ‘All infections’, 
‘Hospitalization for infection’, and ‘Death from infection’, shown separately for the high-dose 
group versus the low-dose group. 
 
Figure 6. Forest plot showing hazard ratios and interaction P values for ‘All infections’ and 
‘Hospitalization for infection’ for all subjects in the trial, and separated according to patients 
dialyzing on a fistula only for the whole study versus those dialyzing on a catheter only. Data are 
adjusted for stratification variables (vascular access, diabetic status, and time on dialysis). 
 
Figure 7. Proportion of causal infectious organisms for all patients randomized in PIVOTAL 
where an infectious agent was identified. 
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Table 1. Characteristics of patients at baseline by vascular access type 
 
Variable 
All subjects 
(n=2141) 
Catheter at 
baseline (n=877) 
Fistula/graft at 
baseline 
(n=1264) P-value 
Age (years) 62.8 ( 15.01) 61.2 ( 15.69) 63.9 ( 14.41) <0.001 
Males 1398 ( 65.30%) 556 ( 63.40%) 842 ( 66.61%) 0.124 
     
Ethnicity     
White 1698 ( 79.31%) 662 ( 75.48%) 1036 ( 81.96%) <0.001 
Black 190 (  8.87%) 98 ( 11.17%) 92 (  7.28%)  
Asian 185 (  8.64%) 79 (  9.01%) 106 (  8.39%)  
Other 68 (  3.18%) 38 (  4.33%) 30 (  2.37%)  
     
Duration of dialysis 
treatment (months)* 
4.8 (  2.83,   8.22) 4.3 (  2.66,   7.11) 5.3 (  2.98,   8.96) <0.001 
AF 164 (  7.66%) 60 (  6.84%) 104 (  8.23%) 0.236 
Heart failure 86 (  4.02%) 36 (  4.10%) 50 (  3.96%) 0.863 
Hypertension 1557 ( 72.72%) 609 ( 69.44%) 948 ( 75.00%) 0.005 
hyperlipidaemia 535 ( 24.99%) 197 ( 22.46%) 338 ( 26.74%) 0.079 
PVD 187 (  8.73%) 83 (  9.46%) 104 (  8.23%) 0.319 
MI 184 (  8.59%) 64 (  7.30%) 120 (  9.49%) 0.075 
Stroke 176 (  8.22%) 69 (  7.87%) 107 (  8.47%) 0.621 
Diabetes 950 ( 44.37%) 403 ( 45.95%) 547 ( 43.28%) 0.220 
     
Smoking status     
Current 249 ( 11.63%) 111 ( 12.66%) 138 ( 10.92%) 0.466 
Former 545 ( 25.46%) 220 ( 25.09%) 325 ( 25.71%)  
Never 1347 ( 62.91%) 546 ( 62.26%) 801 ( 63.37%)  
     
Weight (kg) 82.1 ( 20.96) 80.3 ( 21.16) 83.3 ( 20.73) 0.001 
BMI (kg/m2) 28.7 (  6.91) 28.2 (  6.95) 29.1 (  6.86) 0.003 
SBP(mmHg) 144.7 ( 23.68) 147.6 ( 24.28) 142.8 ( 23.06) <0.001 
DBP(mmHg) 73.6 ( 14.80) 75.8 ( 15.16) 72.1 ( 14.36) <0.001 
Haemoglobin (g/L) 105.6 ( 13.74) 104.3 ( 13.98) 106.4 ( 13.50) <0.001 
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Variable 
All subjects 
(n=2141) 
Catheter at 
baseline (n=877) 
Fistula/graft at 
baseline 
(n=1264) P-value 
Ferritin(ug/L)* 216.0 (133.00, 
304.00) 
204.0 (127.00, 
294.00) 
225.0 (137.00, 
312.00) 
0.010 
TSAT (%)* 20.0 ( 16.00,  
24.00) 
19.0 ( 15.00,  
23.00) 
20.0 ( 16.00,  
24.00) 
<0.001 
CRP (mg/L)* 6.0 (  3.70,  14.00) 6.5 (  4.00,  14.00) 6.0 (  3.50,  14.00) 0.331 
Standardised monthly 
ESA dose* 
8000.0 (5000.0,  
12000) 
8000.0 (6000.0,  
12000) 
6000.0 (4000.0,  
10000) 
0.006 
     
Primary Cause of Kidney 
Disease 
    
Hypertension 235 ( 10.98%) 88 ( 10.03%) 147 ( 11.63%) 0.001 
Diabetic Nephropathy 712 ( 33.26%) 319 ( 36.37%) 393 ( 31.09%)  
Glomerular Disease 394 ( 18.40%) 171 ( 19.50%) 223 ( 17.64%)  
Tubulointerstitial 
Disease 
201 (  9.39%) 83 (  9.46%) 118 (  9.34%)  
Renovascular Disease 147 (  6.87%) 55 (  6.27%) 92 (  7.28%)  
Other 129 (  6.03%) 59 (  6.73%) 70 (  5.54%)  
Polycystic Kidney 
Disease 
117 (  5.46%) 29 (  3.31%) 88 (  6.96%)  
Unknown 206 (  9.62%) 73 (  8.32%) 133 ( 10.52%)  
     
Proactive Randomised 
Treatment 
1093 ( 51.05%) 449 ( 51.20%) 644 ( 50.95%) 0.910 
 
 For categorical variables number and percentage are reported 
 For continuous variables mean and standard deviation are reported except for variables  
with an asterisk where median and inter-quartile range are presented 
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Table 2. Association between iron dose; ferritin; TSAT and risk of infection 
Association analyzed Reactive low-dose iron group Proactive high-dose iron group 
HR 95% CI P value HR 95% CI P value 
Most recent IV iron dose (per 
100 mg) and any infection 
1.03 0.96, 1.10 0.41 1.02 0.97, 1.06 0.45 
Current total IV iron dose  
(per 100 mg) and any 
infection 
1.00 0.98, 1.01 0.42 1.00 0.99, 1.01 0.50 
Most recent ferritin (per 100 
µg/L) and any infection 
1.04 0.98, 1.10 0.16 0.97 0.93, 1.01 0.12 
Most recent TSAT (per 5%) 
and any infection 
0.90 0.85, 0.96 0.0007 0.97 0.92, 1.01 0.15 
Most recent IV iron dose (per 
100 mg) and hospitalized 
infection 
1.00 0.92, 1.08 0.95 1.05 0.99, 1.10 0.11 
Current total IV iron dose 
(per 100 mg) and 
hospitalized infection 
1.00 0.99, 1.02 0.45 1.00 0.99, 1.01 0.53 
Most recent ferritin (per 100  
µg/L) and hospitalized 
infection 
1.08 1.03, 1.14 0.001 0.95 0.90, 1.00 0.037 
Most recent TSAT (per 5%) 
and hospitalized infection 
0.88 0.82, 0.95 0.0009 0.92 0.87, 0.98 0.0056 
 
 
 
 
 
 
